MDS

In an interview with CURE, Rami Komrokji, M.D., a hematologist at Moffitt Cancer Center in Tampa, Florida, discusses the advances that have been made in MDS in the past few years, as well as the MDS Clinical Research Consortium and its importance.

MDS is a rare form of cancer with its own unique characteristics. Here is one patients perspective on the experience of having MDS.

An intensive preparatory stem cell transplant (SCT) regimen should be used for younger patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), according to the results of a phase 3 clinical trial.

ClearLLab multicolor reagents (T1, T2, B1, B2, M) gained approval from the Food and Drug Administration (FDA) to detect chronic leukemia, acute leukemia, non-Hodgkin lymphoma, multiple myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). This is the first approval the agency received for immunophenotyping on a flow cytometer.

What do oncology nurses mean to their patients? This is an inside view from one grateful patient.

Revlimid is showing promise for patients with low-risk MDS, according to the results of a recent study.

High cost does not always mean better chances of survival for elderly patients with MDS, according to a recent study.

An essay honoring Emily A. Knight, RN, OCN [Mayo Clinic Cancer Center in Scottsdale, Arizona.

Ruben A. Mesa addressed the current treatment landscape for PV last week at the 33rd Annual Chemotherapy Foundation Symposium, a meeting of over 1,000 physicians and other oncology professionals.

CURE interviewed Thomas Prebet to gain insight into the importance of supportive care in myelodysplastic syndrome.

Aziz Nazha, Hematology and Medical Oncology Fellow, Cleveland Clinic, discusses adverse events associated with treatment for myelodysplastic syndrome (MDS).

Aziz Nazha, Hematology and Medical Oncology Fellow, Cleveland Clinic, discusses the future of treating patients with myelodysplastic syndrome (MDS).

Treatment strategies for patients with MDS are built upon a foundation of supportive care, which consists of transfusions, iron chelation, and growth factor therapy.

The Food and Drug Administration (FDA) has approved Jadenu (deferasirox) for the treatment of chronic iron overload, a condition that can affect patients with myelodysplastic syndromes (MDS), sickle cell disease and thalassemia.

Lewis Silverman, an oncologist with Mount Sinai Medical Center, discusses a clinical trial involving Revlimid (lenalidomide) for patients with a type of myelodysplastic syndrome.

Robin Roberts, who was one of the most influential people in cancer last year, returns to "Good Morning America" today after recovering from MDS and a bone marrow transplantation.